Steffen D Kriechbaum1, Niklas F Boeder2, Luise Gaede3, Martin Arnold3, Ursula Vigelius-Rauch4, Peter Roth5, Michael Sander4, Andreas Böning5, Matthias Bayer2, Albrecht Elsässer6, Helge Möllmann7, Christian W Hamm2, Holger M Nef2. 1. Department of Cardiology and Angiology, Medical Clinic I, Universitätsklinikum Gießen and Marburg, University of Giessen, Klinikstraße 33, 35392, Giessen, Germany. steffen.kriechbaum@uk-gm.de. 2. Department of Cardiology and Angiology, Medical Clinic I, Universitätsklinikum Gießen and Marburg, University of Giessen, Klinikstraße 33, 35392, Giessen, Germany. 3. Medical Clinic 2, University Hospital of Erlangen, Giessen, Germany. 4. Department of Anaesthesiology, University of Giessen, Giessen, Germany. 5. Department of Adult and Paediatric Cardiovascular Surgery, University of Giessen, Giessen, Germany. 6. Department of Cardiology, University of Oldenburg, Oldenburg, Germany. 7. Medical Clinic I, Department of Cardiology, St-Johannes-Hospital, Dortmund, Germany.
Abstract
AIMS: To examine the clinical experience and practical use of the PASCAL transcatheter valve repair system (Edwards Lifesciences, Irvine, CA, USA) and to report some of the first clinical results. METHODS AND RESULTS: A total of 18 consecutive patients with severe, symptomatic mitral regurgitation (MR) were included in this German multicentre registry. All patients underwent clinical, echocardiographic, and laboratory assessment prior to the PASCAL procedure and before hospital discharge. MR was classified as functional in 6 patients, degenerative in 2, and combined in 10. All except one received a single PASCAL implant. The preprocedural severe MR present in all patients was reduced: grade 0 in 4 (22.2%), grade I in 11 (61.1%), grade II in 3 (16.7%). The v-wave was significantly reduced from 31.7 ± 9.5 to 18 ± 7.7 mmHg (p < 0.001). Independent leaflet capture, performed in 4 (22.2%) of the patients, wide clasps, and the 10-mm central spacer are features of the PASCAL device to optimize mitral leaflet repair. There were no periprocedural complications. CONCLUSION: PASCAL is a safe and effective mitral valve repair device for the treatment of severe MR. Device-specific features allow valve repair tailored to the individual anatomy of the underlying mitral pathology in each patient.
AIMS: To examine the clinical experience and practical use of the PASCAL transcatheter valve repair system (Edwards Lifesciences, Irvine, CA, USA) and to report some of the first clinical results. METHODS AND RESULTS: A total of 18 consecutive patients with severe, symptomatic mitral regurgitation (MR) were included in this German multicentre registry. All patients underwent clinical, echocardiographic, and laboratory assessment prior to the PASCAL procedure and before hospital discharge. MR was classified as functional in 6 patients, degenerative in 2, and combined in 10. All except one received a single PASCAL implant. The preprocedural severe MR present in all patients was reduced: grade 0 in 4 (22.2%), grade I in 11 (61.1%), grade II in 3 (16.7%). The v-wave was significantly reduced from 31.7 ± 9.5 to 18 ± 7.7 mmHg (p < 0.001). Independent leaflet capture, performed in 4 (22.2%) of the patients, wide clasps, and the 10-mm central spacer are features of the PASCAL device to optimize mitral leaflet repair. There were no periprocedural complications. CONCLUSION: PASCAL is a safe and effective mitral valve repair device for the treatment of severe MR. Device-specific features allow valve repair tailored to the individual anatomy of the underlying mitral pathology in each patient.
Authors: Ted Feldman; Elyse Foster; Donald D Glower; Donald G Glower; Saibal Kar; Michael J Rinaldi; Peter S Fail; Richard W Smalling; Robert Siegel; Geoffrey A Rose; Eric Engeron; Catalin Loghin; Alfredo Trento; Eric R Skipper; Tommy Fudge; George V Letsou; Joseph M Massaro; Laura Mauri Journal: N Engl J Med Date: 2011-04-04 Impact factor: 91.245
Authors: Robert Schueler; Can Öztürk; Jan-Malte Sinning; Nikos Werner; Armin Welz; Christoph Hammerstingl; Georg Nickenig Journal: Clin Res Cardiol Date: 2016-12-21 Impact factor: 5.460
Authors: Mariana Mirabel; Bernard Iung; Gabriel Baron; David Messika-Zeitoun; Delphine Détaint; Jean-Louis Vanoverschelde; Eric G Butchart; Philippe Ravaud; Alec Vahanian Journal: Eur Heart J Date: 2007-03-09 Impact factor: 29.983
Authors: D Scott Lim; Saibal Kar; Konstantinos Spargias; Robert M Kipperman; William W O'Neill; Martin K C Ng; Neil P Fam; Darren L Walters; John G Webb; Robert L Smith; Michael J Rinaldi; Azeem Latib; Gideon N Cohen; Ulrich Schäfer; Leo Marcoff; Prashanthi Vandrangi; Patrick Verta; Ted E Feldman Journal: JACC Cardiovasc Interv Date: 2019-06-26 Impact factor: 11.195
Authors: Nicolas A Geis; Philipp Schlegel; Markus B Heckmann; Hugo A Katus; Norbert Frey; Patricia Crespo López; Philip W J Raake Journal: ESC Heart Fail Date: 2022-02-15
Authors: Zhang Xiling; Thomas Puehler; Lars Sondergaard; Derk Frank; Hatim Seoudy; Baland Mohammad; Oliver J Müller; Stephanie Sellers; David Meier; Janarthanan Sathananthan; Georg Lutter Journal: J Clin Med Date: 2022-06-13 Impact factor: 4.964